Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis.
The antileishmanial property of a Benzyl derivative of a new antibiotic MT81 (Bz2MT81), isolated and purified from a fungal strain of Penicillium nigricans NRRL 917 was tested in free, liposome intercalated and mannose coated liposome intercalated forms in vivo against visceral leishmaniasis in hamsters. Mannose grafted liposome intercalated Bz2MT81 eliminated intracellular amastigotes of Leishmania donovani within splenic macrophages more efficiently than the liposome intercalated Bz2MT81 or free Bz2MT81. At a dose equivalent to 7.5 microg/Kg body weight when injected subcutaneously (s.c) in mannose grafted liposome intercalated form for 15 days in an interval of three days, the splenic parasitic load decreased to the extent of 79.1% of the total parasite present in infected control animals. Whereas, an identical amount (7.5 mug/Kg body weight) of Bz2MT81 in free or liposome intercalated form was found less effective in controlling the parasite in spleen (in free Bz2MT81 form, suppression of parasitic load is 49.8% and in liposome intercalated form, it is 55.1%). Both mannosylated liposomes and Bz2MT81 were noted non-toxic to the host peritoneal macrophages. Histological examinations of spleen and liver, kidney function tests (SGPT, alkaline phosphatase, creatinine and urea in blood plasma) showed that the toxicity of Bz2MT81 was reduced up to normal level when mannose grafted liposomal Bz2MT81 were administered.
Mitra
Maitreyi
M
Jadavpur University, Department of Pharmaceutical Technology, Kolkata, 700 032, India.
Mandal
Ardhendu K
AK
Chatterjee
Tapan Kumar
TK
Das
Nirmalendu
N
D000818:Animals; D000880:Anthraquinones / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003208:Concanavalin A / Q000494:pharmacology; D006224:Cricetinae; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005079:Excipients; D005452:Fluoresceins; D005456:Fluorescent Dyes; D007364:Intercalating Agents / Q000494:pharmacology; D007677:Kidney Function Tests; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D008081:Liposomes / Q000737:chemistry*; D008111:Liver Function Tests; D008264:Macrophages / Q000187:drug effects; D008358:Mannose / Q000737:chemistry*; D008647:Mesocricetus; D051379:Mice; D008807:Mice, Inbred BALB C; D012157:Mononuclear Phagocyte System / Q000187:drug effects*; D010316:Particle Size; D010407:Penicillium / Q000737:chemistry*; D014302:Trinitrobenzenesulfonic Acid / Q000494:pharmacology; D014343:Trypan Blue
D000880:Anthraquinones; D000981:Antiprotozoal Agents; D001593:Benzyl Compounds; D004337:Drug Carriers; D005079:Excipients; D005452:Fluoresceins; D005456:Fluorescent Dyes; D007364:Intercalating Agents; D008081:Liposomes; D003208:Concanavalin A; C024098:6-carboxyfluorescein; C076604:MT81 mycotoxin; D014302:Trinitrobenzenesulfonic Acid; D014343:Trypan Blue; D008358:Mannose